The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins ...

Teplizumab is thought to work by preventing the activation of T-cells that attack those cells. In a clinical trial, Tzield given once daily as an intravenous infusion for 14 days to patients with ...

Teplizumab can delay the onset of the chronic disease by reprogramming the immune system to stop it mistakenly attacking pancreatic cells which produce insulin. Sam, 14, from Kings Norton ...